Aug 5 (Reuters) - IntelliPharmaCeutics International Inc I.TO :
* Updates status of tentative approvals of generic focalin Xr(R)
* FDA reinstated a previously-imposed requirement that the company's
tentatively-approved strengths of its generic focalin
* Says strengths affected are 5 mg, 10 mg, 20 mg and 40 mg
* Already-approved 15 mg and 30 mg strengths of its generic focalin xrcapsules
now in market are not affected
* FDA needs strengths of generic focalin xr capsules will have to meet new
conditions for bioequivalence prior to getting approval
* Says new bioequivalence requirements also do not apply to any of co's other
drug product candidate applications
* Says "we are, of course, disappointed by this unexpected action by the FDA"
* Source text for Eikon ID:nGNXVEDYWa
* Further company coverage I.TO